Format

Send to

Choose Destination
Int Forum Allergy Rhinol. 2019 Nov 6. doi: 10.1002/alr.22471. [Epub ahead of print]

Treatment practices for aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.

Author information

1
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA.
2
Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, GA.
3
Department of Biostatistics, Emory University, Atlanta, GA.
4
Division of Allergy, Pulmonary, Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.
5
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA.
6
Department of Medicine, Harvard Medical School, Boston, MA.
7
Division of Allergy and Immunology, Emory University, Atlanta, GA.

Abstract

BACKGROUND:

Aspirin-exacerbated respiratory disease (AERD) is the triad of asthma, nasal polyposis, and sensitivity to cyclooxygenase-1 inhibitors. Treatment options include medical management, surgical intervention, and aspirin desensitization (AsaD).

METHODS:

AERD patients were identified using the MarketScan Database from 2009 to 2015. Patients were included using International Classification of Diseases, 9th edition (ICD-9) codes for asthma, nasal polyposis, and drug allergy. Treatments were determined by Current Procedural Terminology (CPT) codes for drug desensitization and endonasal procedures. Geographic trends and timing of interventions between those exposed and not exposed to desensitization were explored.

RESULTS:

A total of 5628 patients met inclusion criteria for AERD, with mean age 46 years, 60% female; 395 (7%) underwent AsaD and 2171 (39%) underwent sinus surgery. Among patients who were desensitized, 229 (58%) underwent surgery, of whom 201 (88%) had surgery prior to AsaD (median [quartile 1, quartile 3]; 61 days [30, 208] prior to desensitization). For patients undergoing surgery following AsaD (n = 46), surgery was performed a median of 302 (163, 758) days after AsaD. Nineteen patients had multiple surgeries post-AsaD with median time between surgeries being 734 days (312, 1484); 261 patients were not desensitized to aspirin but did undergo multiple surgeries, with the median of the median time between surgeries being 287 days (15, 617), which is shorter than for patients post-AsaD (p < 0.001).

CONCLUSION:

A very small percentage of AERD patients undergo AsaD. Patients who had AsaD underwent surgery approximately 2 months prior to AsaD. Patients who underwent AsaD experienced an increased time between surgeries compared to patients who did not undergo AsaD.

KEYWORDS:

AERD; aspirin desensitization; asthma; chronic rhinosinusitis; sinusitis

PMID:
31693796
DOI:
10.1002/alr.22471

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center